<DOC>
	<DOCNO>NCT00412750</DOCNO>
	<brief_summary>To evaluate combination telbivudine 600 mg orally ( PO ) daily peginterferon alpha-2a 180 ug subcutaneous ( sq ) injection weekly antiviral efficacy comparison peginterferon alpha-2a monotherapy .</brief_summary>
	<brief_title>Efficacy Safety Telbivudine Treatment naïve Patients With Hepatitis B e Antigen ( HBeAg ) -Positive Chronic Hepatitis B ( CHB )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Documented Chronic hepatitis B ( CHB ) define follow : Clinical history compatible CHB Detectable serum Hepatitis B Surface Antigen ( HBsAg ) Screening visit least 6 month prior HBeAgpositive Screening visit Hepatitis B ' e ' Antibody ( HBeAb ) negative Screening visit History evidence chronic liver inflammation , Elevated serum Alanine aminotransferase ( ALT ) level ( 1.3 10 x upper limit normal ( ULN ) ) Screening visit Serum HBV DNA level ≥ 6 log10 copies/mL , Chronic liver inflammation previous liver biopsy within previous 24 month . Coinfection Hepatitis C Virus ( HCV ) , Hepatitis D Virus ( HDV ) , Human Immunodeficiency Virus ( HIV ) . Has follow drug therapy : Previously treat trial telbivudine Received nucleoside nucleotide therapy whether approved investigational Received immunomodulatory treatment 12 month Screening study . Has medical condition require prolonged frequent use systemic acyclovir famciclovir . Has medical condition require frequent prolong use systemic corticosteroid although inhaled intraarticular corticosteroid allow . Has medical condition require chronic prolong use potentially hepatotoxic drug nephrotoxic drug . Is currently abuse alcohol illicit drug history alcohol abuse illicit substance abuse within precede two year . Uses investigational drug time enrollment , within 30 day 5 halflives enrollment , whichever long . Is currently receive methadone . Patient following : History clinical signs/symptoms hepatic decompensation ascites , esophageal variceal bleeding , hepatic encephalopathy , spontaneous bacterial peritonitis . History malignancy organ system , treat untreated , within past 5 year whether evidence local recurrence metastasis , exception localize basal cell carcinoma skin . Patients previous finding suggestive possible HCC disease rule prior entrance study . One additional know primary secondary cause liver disease hepatitis B , include steatohepatitis . History clinical laboratory evidence chronic pancreatitis , demonstrate clinical laboratory course consistent current pancreatitis . Has laboratory value screen visit within normal limit . Is pregnant breastfeeding . Is woman childbearing potential unwilling practice birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>hepatitis B</keyword>
	<keyword>hepatitis B Virus ( HBV )</keyword>
	<keyword>chronic hepatitis B</keyword>
	<keyword>telbivudine</keyword>
	<keyword>peginterferon</keyword>
</DOC>